SynthesisThe Cochrane database of systematic reviews2008
Cannabis and schizophrenia.
Synthesis in The Cochrane database of systematic reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Cannabis and schizophrenia.The Cochrane database of systematic reviews · 2014Pooled it
- Medicinal cannabis: time to lighten up?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014Article
- Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia.European archives of psychiatry and clinical neuroscience · 2013Article
- "But my doctor recommended pot": medical marijuana and the patient-physician relationship.Journal of general internal medicine · 2011Article
- Generalizability of clinical trials for cannabis dependence to community samples.Drug and alcohol dependence · 2010Article
- A retrospective analysis of cannabis use in a cohort of mentally ill patients in Sri Lanka and its implications on policy development.Substance abuse treatment, prevention, and policy · 2010Article
- Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.International immunopharmacology · 2010Review
- Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse.Psychopharmacology · 2010Article
- Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.CNS drugs · 2009Review
- Cannabis and schizophrenia spectrum disorders: a review of clinical studies.Indian journal of psychological medicine · 2009Article
Corrections and comments
- Updated by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany people with schizophrenia use cannabis and its effects on the illness are unclear.
objectivesTo evaluate the effects of cannabis use on people with schizophrenia and schizophrenia-like illnesses. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. SELECTION CRITERIA: We included all randomised trials involving cannabinoids and people with schizophrenia or schizophrenia-like illnesses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis, based on a fixed effects model. We calculated the numbers needed to treat/harm (NNT/NNH). For continuous data, we calculated weighted mean differences (WMD) again based on a fixed effects model. MAIN
resultsWe identified one randomised trial. No significant differences were found between the Cannabis and Psychosis Therapy (CAP) intervention group and the Psychoeducaton (PE) intervention for use of cannabis at three months assessment (n=47, RR 1.04 CI 0.6 to 1.7). BPRS-extended scale scores at three months assessment (n=47, WMD -3.60 CI -12.8 to 5.6) and nine months assessment (n=47, WMD 0.80 CI -7.5 to 9.1) were non-significant between CAP and PE. We found no significant improvement in social functioning in the CAP group compared with PE (at 3 months, n=47, WMD -0.80 CI -10 to 8.4) and (at 9 months, n=47, WMD -4.70 CI -14.5 to 5.1). AUTHORS'
conclusionsAt present, there is insufficient evidence to support or refute the use of cannabis/cannabinoid compounds for people suffering with schizophrenia. This review highlights the need for well designed, conducted and reported clinical trials to address the potential effects of cannabis based compounds for people with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.